Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
drainAD: Thiethylperazine in Early-to-Mild Alzheimer's Disease
NCT03417986Phase 2Completed
- Sponsor
- Immungenetics AG
- Start
- Nov 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thiethylperazine in Alzheimer's disease (AD), sponsored by Immungenetics AG. Started Nov 2017; status: completed.
02
Drugs
thiethylperazine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03417986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417986.